Prof. Anders Waage

Prof. Anders Waage is one of Scandinavia's most distinguished hematologists, holding a joint appointment at St. Olavs Hospital and the Norwegian University of Science and Technology (NTNU) in Trondheim. Over a career of more than 30 years, he has combined an active clinical practice managing patients with hematological malignancies — particularly multiple myeloma — with a highly productive research program that has shaped myeloma treatment in the Nordic region and internationally. Prof. Waage is a founding member and key contributor to the Nordic Myeloma Study Group, a collaborative research network that has produced landmark studies on myeloma biology, novel treatment regimens, and real-world outcomes in Scandinavian populations. He has published more than 300 peer-reviewed articles and is a sought-after speaker at international hematology congresses. Clinically, he leads a comprehensive myeloma program at St. Olavs Hospital that offers state-of-the-art treatment including novel proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous stem cell transplantation.

Prof. Anders Waage completed his MD at NTNU (then known as the University of Trondheim), followed by his PhD in hematology, with doctoral research focused on the molecular biology of multiple myeloma and cytokine regulation of tumor growth. His hematology specialist training was completed at St. Olavs Hospital, Trondheim, and included periods of research and clinical training at leading hematology centers in Sweden and the United Kingdom. Prof. Waage has been a visiting scientist at international research institutions studying plasma cell biology, immunotherapy, and the tumor microenvironment in multiple myeloma. He holds a full professorship at NTNU's Faculty of Medicine and Health Sciences and has supervised more than a dozen PhD candidates in hematological oncology. He is a member of the European Hematology Association and the American Society of Hematology.

Prof. Waage's clinical expertise spans the full management of plasma cell dyscrasias and lymphoid malignancies. In multiple myeloma, he is skilled in all aspects of disease management from initial workup and staging through frontline treatment, transplant evaluation, and management of relapsed/refractory disease. He integrates the latest evidence from international trials including the use of daratumumab-based quadruplet induction regimens, novel maintenance strategies, and chimeric antigen receptor (CAR) T-cell therapy evaluation. His expertise in smoldering myeloma includes risk-stratified monitoring and evidence-based decisions about early treatment initiation. In lymphoma, he manages both Hodgkin and non-Hodgkin lymphoma subtypes. He leads the stem cell transplant program, encompassing autologous and, for selected patients, allogeneic transplantation. He also manages rare plasma cell conditions including AL amyloidosis and Waldenström's macroglobulinemia.

St. Olavs Hospital in Trondheim is a major university hospital that welcomes international patients, particularly those seeking expert hematological evaluation and treatment for complex conditions such as multiple myeloma. Prof. Waage's practice offers consultations in English and Norwegian. The hospital's international patient services team assists with appointment coordination, translation, and accommodation referrals in Trondheim. For international patients seeking second opinions on myeloma management without traveling to Norway, telemedicine consultations are available, during which Prof. Waage reviews medical records, imaging, and bone marrow reports and provides detailed written recommendations.

Prof. Anders Waage has received numerous honors recognizing his contributions to hematology and myeloma research. He has received multiple research awards from the Norwegian Cancer Society and the Nordic Cancer Union for his work in multiple myeloma. He has served as an invited speaker and plenary presenter at the American Society of Hematology Annual Meeting, the European Hematology Association Congress, and the International Myeloma Workshop. He has received lifetime achievement recognition from the Nordic Myeloma Study Group for his decades of leadership in advancing myeloma treatment across Scandinavia. His publication record of more than 300 papers includes seminal contributions to understanding myeloma cytogenetics, treatment sequencing, and maintenance therapy.